Phillip V. DeFedele counsels clients in the life sciences and healthcare industries on regulatory, transactional, compliance, and enforcement matters. His areas of focus include FDA regulation of drugs, devices, and biologics, fraud and abuse, research and development, advertising and promotion, and compliance programs. Mr. DeFedele also conducts regulatory due diligence in connection with business transactions and assists in drafting and negotiating various contractual arrangements.
Perspectives
November 25, 2020
HHS Finalizes New Protections Under the Stark Law for Value-Based Arrangements and Makes Other Critical Revisions and Clarifications to the Regulations that Physicians and Designated Health Service Entities Must Understand
Advisory
November 23, 2020
Final FDA Guidance Reinforces Increased Focus on Diversity and Inclusion in Clinical Development
Advisory
October 9, 2020
Guide to the Trump Administration's Drug Importation Final Rule and Guidance
Advisory
April 3, 2020
Update on Medical Products Shortage Reporting: What Manufacturers Need to Know Regarding FDA's New Reporting Guidance and Expanded Reporting Under the CARES Act
Coronavirus: Life Sciences and Healthcare Regulatory Advisory
More
Credentials
Education
- JD, Health Law, Seton Hall University School of Law, 2015, summa cum laude, valedictorian
- BA, History, Italian minor, The College of New Jersey, 2011
Admissions
- New York
- New Jersey